Description
The abstract claims PIKFYVE inhibition ameliorates multiple ALS forms, suggesting a common downstream pathway despite diverse genetic causes. The convergent mechanism that makes this pan-ALS therapeutic approach effective remains unexplained but could reveal fundamental disease processes.
Gap type: unexplained_observation Source paper: PIKFYVE inhibition mitigates disease in models of diverse forms of ALS. (2023, Cell, PMID:36754049)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:22.317574+00:00”, “resolution_summary”: “Resolved by hypothesis h-9025d807: PIKFYVE Inhibition Activates Aggregate Exocytosis via PI(3,5)P2→TRPML1→Calcineurin→TFEB Cascade in ALS Motor Neurons. Supporting evidence includes debate sess_SDA-2026-04-07-gap-pubmed-20260406-062212-ca78691c_task_9aae8fc5.”, “match_counts”: {“hypothesis_matches”: 3, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-9025d807”, “title”: “PIKFYVE Inhibition Activates Aggregate Exocytosis via PI(3,5)P2→TRPML1→Calcineurin→TFEB Cascade in ALS Motor Neurons”, “score”: 0.343, “reason”: “15 token overlaps; entity overlap: als, pikfyve”, “analysis_id”: “SDA-2026-04-13-gap-pubmed-20260410-143119-8ae42941”, “target_gene”: “PIKFYVE/MCOLN1/PPP3CB/TFEB”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.5840000000000001, “confidence_score”: 0.55, “status”: “promoted”, “pubmed_evidence_ids”: [“26702100”, “27357649”, “35144097”, “37414766”, “37909662”]}, {“id”: “h-var-a0933e666d”, “title”: “Microglial AIM2 Inflammasome as the Primary Driver of TDP-43 Proteinopathy Neuroinflammation in ALS/FTD”, “score”: 0.221, “reason”: “17 token overlaps; entity overlap: als”, “analysis_id”: “SDA-2026-04-01-gap-20260401-225149”, “target_gene”: “AIM2, CASP1, IL1B, PYCARD, TARDBP”, “target_pathway”: “Microglial AIM2 inflammasome activation via phagocytosed neuron-derived mtDNA in TDP-43 proteinopathy”, “disease”: “neurodegeneration”, “composite_score”: 0.8240000000000001, “confidence_score”: 0.76, “status”: “proposed”, “pubmed_evidence_ids”: [“27519954”, “28506519”, “29263430”, “29643512”, “30610225”]}, {“id”: “h-6fe30c39bc”, “title”: “STING Antagonists as ALS Therapeutics: Drug Repurposing”, “score”: 0.22, “reason”: “17 token overlaps; entity overlap: als”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062141-fc60e018”, “target_gene”: “STING (TMEM173)”, “target_pathway”: null, “disease”: “neuroinflammation”, “composite_score”: 0.771164, “confidence_score”: 0.68, “status”: “proposed”, “pubmed_evidence_ids”: [“29346698”, “33031745”, “33147677”, “34644542”, “41380972”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062212-ca78691c_task_9aae8fc5”, “title”: “The abstract identifies that neurons show resistance to autophagy induction, but the mechanistic basis remains incompletely defined. Understanding this resistance is crucial for developing neuron-targeted autophagy therapies for ALS.\n\nGap type: unexplained_observation\nSource paper: Autophagy and ALS: mechanistic insights and therapeutic implications. (2022, Autophagy, PMID:34057020)”, “score”: 0.591, “reason”: “11 token overlaps; entity overlap: als, pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062212-ca78691c”, “quality_score”: 0.65, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-08-gap-pubmed-20260406-062111-db808ee9”, “title”: “The abstract notes that clinical presentations overlap across different myelopathy etiologies, but the mechanistic basis for this convergent phenotype is not explained. Resolving this could improve differential diagnosis and reveal common therapeutic targets.\n\nGap type: unexplained_observation\nSource paper: Uncommon inflammatory/immune-related myelopathies. (2021, J Neuroimmunol, PMID:34715593)”, “score”: 0.538, “reason”: “14 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-08-gap-pubmed-20260406-062111-db808ee9”, “quality_score”: 0.86, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-08-gap-pubmed-20260406-062141-739c7f1c_task_9aae8fc5”, “title”: “While the study demonstrates TDP-43 triggers mPTP-mediated mtDNA release, the molecular mechanism by which TDP-43 pathology leads to mPTP opening is not explained. Identifying this upstream trigger could reveal more proximal therapeutic targets than downstream cGAS/STING inhibition.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS. (2020, Cell, PMID:33031745)”, “score”: 0.534, “reason”: “10 token overlaps; entity overlap: als, pmid”, “analysis_id”: “SDA-2026-04-08-gap-pubmed-20260406-062141-739c7f1c”, “quality_score”: 0.772, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-13-gap-pubmed-20260410-170057-1bea7d88_20260413-225852”, “title”: “The study shows VCP-mutant astrocytes exhibit hypoxia response activation without actual hypoxia, but the mechanistic link between VCP dysfunction and HIF-1α stabilization remains unexplained. Understanding this connection is critical for developing targeted therapies that could prevent early pathogenic events in VCP-ALS.\n\nGap type: unexplained_observation\nSource paper: Hypoxic stress is an early pathogenic event in human VCP-mutant ALS astrocytes. (2026, Stem cell reports, PMID:41349534)”, “score”: 0.511, “reason”: “10 token overlaps; entity overlap: als, pmid”, “analysis_id”: “SDA-2026-04-13-gap-pubmed-20260410-170057-1bea7d88”, “quality_score”: 0.78, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062141-611cf046_task_9aae8fc5”, “title”: “While the study establishes TDP-43 triggers mtDNA release via mPTP to activate cGAS/STING, it’s unclear why this pathway preferentially affects motor neurons in ALS when TDP-43 pathology occurs in multiple cell types. Understanding this selectivity is crucial for targeted therapeutic interventions.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS. (2020, Cell, PMID:33031745)”, “score”: 0.501, “reason”: “9 token overlaps; entity overlap: als, pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062141-611cf046”, “quality_score”: 0.734, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}